Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aurélien Amiot

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Alimentary Pharmacology & Therapeutics|April 8, 2025
Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis. Authors' ReplyAntoine Meyer, Aurélien Amiot
Clinics and Research in Hepatology and Gastroenterology|October 31, 2025
IBD in transition, progresses and challengesDavid Laharie, Aurélien Amiot, Lucine Vuitton
Alimentary Pharmacology & Therapeutics|April 13, 2023
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisationAntoine Meyer, Aurélien Amiot, Franck Carbonnel
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' replyHadrien Alric, Aurélien Amiot, Franck Carbonnel, et al.
Journal of Crohn'S & Colitis|May 12, 2026
Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitorsAntoine Meyer, Anaïs Bertrand, Antoine Martin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2026
Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylatesAnaïs Bertrand, Aurélien Amiot, Antoine Martin, et al.
Clinics and Research in Hepatology and Gastroenterology|September 21, 2017
Endoscopic training: A nationwide survey of French fellows in gastroenterologyAurélien Amiot, Guillaume Conroy, Yann Le Baleur, et al.
Clinics and Research in Hepatology and Gastroenterology|November 9, 2025
Expert opinion on hot topics in the field of IBDLucine Vuitton, Marianne Hupé, Lucien Grados, et al.
Gastroenterologie Clinique Et Biologique|November 1, 2006
[Chronic intestinal pseudo-obstruction]Francisca Joly, Aurélien Amiot, Benoît Coffin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 8, 2020
Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensusAurélien Amiot, Guillaume Bouguen, Guillaume Bonnaud, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Alimentary Pharmacology & Therapeutics|April 8, 2025
Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis. Authors' ReplyAntoine Meyer, Aurélien Amiot
Clinics and Research in Hepatology and Gastroenterology|October 31, 2025
IBD in transition, progresses and challengesDavid Laharie, Aurélien Amiot, Lucine Vuitton
Alimentary Pharmacology & Therapeutics|April 13, 2023
Editorial: in search of environmental risk factors of Crohn's disease and ulcerative colitis with mendelian randomisationAntoine Meyer, Aurélien Amiot, Franck Carbonnel
Alimentary Pharmacology & Therapeutics|July 14, 2020
Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' replyHadrien Alric, Aurélien Amiot, Franck Carbonnel, et al.
Journal of Crohn'S & Colitis|May 12, 2026
Comparative risk of serious infection in patients with ulcerative colitis treated with JAK inhibitorsAntoine Meyer, Anaïs Bertrand, Antoine Martin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2026
Serious infection in inflammatory bowel diseases patients treated with vedolizumab, ustekinumab, JAK inhibitors, anti-TNF or aminosalicylatesAnaïs Bertrand, Aurélien Amiot, Antoine Martin, et al.
Clinics and Research in Hepatology and Gastroenterology|September 21, 2017
Endoscopic training: A nationwide survey of French fellows in gastroenterologyAurélien Amiot, Guillaume Conroy, Yann Le Baleur, et al.
Clinics and Research in Hepatology and Gastroenterology|November 9, 2025
Expert opinion on hot topics in the field of IBDLucine Vuitton, Marianne Hupé, Lucien Grados, et al.
Gastroenterologie Clinique Et Biologique|November 1, 2006
[Chronic intestinal pseudo-obstruction]Francisca Joly, Aurélien Amiot, Benoît Coffin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 8, 2020
Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensusAurélien Amiot, Guillaume Bouguen, Guillaume Bonnaud, et al.
Pageof 11